The Efficacy, Safety, And Tolerability of Levofloxacin Quadruple Therapy For *Helicobacter Pylori* Eradication: A Randomized, Double-Blind Clinical Trial

Fariborz Mansour-Ghanaei

Guilan University of Medical Sciences

Behnam Masihpour

Guilan University of Medical Sciences

Mohammad Fathalipour

Hormozgan University of Medical Sciences

Soheil Hassanipour

Guilan University of Medical Sciences

Homayoon Sokhanvar

Guilan University of Medical Sciences

Alireza Mansour-Ghanaei

Guilan University of Medical Sciences

Mehrnaz Asghamezhad

Guilan University of Medical Sciences

Farahnaz Joukar (✉ farajov@gmail.com)

Guilan University of Medical Sciences

Research Article

Keywords: *Helicobacter pylori*, levofloxacin, eradication, adverse drug reaction

Posted Date: July 12th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-53307/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

The incidence of microbial resistance is increasing, and new rescue regimens are needed in order to treat *Helicobacter pylori* (*H. pylori*) infection. To evaluate the efficacy, safety, and tolerability of levofloxacin based quadruple therapies in the eradication of *H. pylori*. In a randomized, double-blind clinical trial, 220 patients with dyspepsia and *H. pylori* infection were randomly assigned to receive either bismuth subcitrate 240 mg, pantoprazole 20 mg, amoxicillin 1000 mg twice a day, and levofloxacin 500 mg daily for seven days (BPAL-7), or ten days (BPAL-10). The eradication of *H. pylori* was evaluated two months after the end of treatment, and adverse drug reactions (ADRs) were assessed during the intervention. According to intention-to-treat and per-protocol, the eradication rate was significantly lower in the BPAL-7 regimen 49.1 % (95 % CI: 39.3-57.8) and 47.6 % (95 % CI: 39.7-58.4), respectively compared to the BPAL-10 regimen 62.7 % (95 % CI: 53.6-72.8) and 62.4 % (95 % CI: 55.1-72.8), respectively. The incidence of ADRs was not statistically significant between BPAL-7 (33.6 %) and BPAL-10 (36.7 %) groups. Although the ADRs were negligible in both groups, these regimens could not be an ideal alternative therapy for *H. pylori* because of low eradication rates compared to standard regimens.

Trial registration: The study reviewed and approved by the Iranian Registry of Clinical Trials (IRCT201406141155N19).

Introduction

Helicobacter pylori (*H. pylori*) affects about 80% of the total population in developing countries and 20–50% in developed countries. The infection as a worldwide health problem is associated with acute and chronic gastritis, peptic ulcer disease, and gastric cancer [1–3]. The eradication of *H. pylori* has a main role in the prevention and treatment of these complications [4, 5]. However, the major concerns of *H. pylori* treatment are low patients compliance, adverse drug reactions (ADRs), and microbial resistance to medicines [6, 7].

The efficacy of present pharmacological treatments for *H. pylori* infection has evaluated in different studies [8–14]. The co-administration of a proton-pump inhibitor (PPI) and two antibiotics (triple therapy), or addition of bismuth salts to the triple therapy (bismuth-based quadruple therapy) for a period of 14 days are the most common regimens [15]. Among antibacterial agents, amoxicillin or metronidazole, along with clarithromycin, are the first-line treatment for eradication of *H. pylori* [9, 16]. Nevertheless, microbial resistance is one of the challenging factors of treatment, which causes low efficacy of these regimens. Hence, effective antibiotics should be selected according to the regional pattern of *H. pylori* resistance [17, 18].

The prevalence of *H. pylori* infection is relatively high among the Iranian population [19, 20]. Moreover, novel strains resisted to clarithromycin and metronidazole are prevalent in some geographical part of Iran [21, 22]. Therefore, a body of evidence suggested new antibiotic regimens with higher efficacy (eradication rate of > 80%), lower ADRs and cost, and acceptable patient compliance. The efficacy of

levofloxacin as a new-generation quinolone in the treatment of *H. pylori* infection has assessed in several studies, and levofloxacin-containing regimens have shown various eradication rates [23–29].

The current study aimed to evaluate the efficacy, safety, and tolerability of seven- and ten-day period of bismuth subcitrate, pantoprazole, amoxicillin, and levofloxacin regimens in the eradication of *H. pylori* among patients referred to Gastrointestinal Outpatient Clinic of Razi hospital, Rasht, Iran.

Methods

Trial design

This study was a phase III open-label, randomized, double-blind controlled trial carried out between July 2015 to November 2015 at Gastrointestinal and Liver Diseases Research Center (GLDRC), Rasht, Iran. All included participants were randomly divided into one of the therapeutic regimens and signed informed consent. The eradication rate of *H. pylori* was assessed two months after the end of the intervention, and the incidence of ADRs and patient compliance were at the end of treatment.

Ethical consideration

The protocol of the study was approved by the local ethical committee of Guilan University of Medical Sciences (Ethics committee code; 1930175713), and also performed according to the declaration of Helsinki for human subjects. The study reviewed and approved by the Iranian Registry of Clinical Trials (IRCT201406141155N19).

Patients

Patients complaining of dyspeptic symptoms referred to the Gastrointestinal Outpatient Clinic of Razi hospital, Rasht, Iran, were enrolled. The main inclusion criteria were a positive rapid urease test and 15 to 65 years of age. Patients with coexisting serious illnesses, including liver cirrhosis, renal failure, heart failure, gastrointestinal malignancies, and history of seizure or hematologic diseases, allergy to medications, and previous incomplete treatment course as well as pregnant or nursing mothers were excluded.

Randomization and intervention

A block randomization method was used in order to assign patients randomly into permuted treatment blocks and ensure equal numbers in each group of treatment. One of these groups received a seven-day period of bismuth subcitrate 240 mg, pantoprazole 20 mg, amoxicillin 1000 mg twice a day, and levofloxacin 500 mg daily (BPAL-7), and the other received a ten-day period of the same regimen (BPAL-10).

Patients were recommended to take bismuth subcitrate, pantoprazole, and levofloxacin before meals, and amoxicillin after meals at the scheduled times. It also advised avoiding smoking, drinking alcoholic or

caffeinated beverages, eating spicy foods, and taking non-steroidal anti-inflammatory drugs or medications containing a monoamine oxidase inhibitor.

Demographic criteria, including age, gender, cigarette smoking, and alcohol drinking, were recorded.

Evaluation of *H. pylori* eradication

Two months after the end of the intervention, a Heliprobe ^{14}C -Urea Breath Test (^{14}C -UBT, Kibion AB, Uppsala, Sweden) with a 95% sensitivity and 100% specificity was performed to evaluate the *H. pylori* eradication. The treatment success was defined as the result of < 50 disintegrations per minute (DPM). Taking the medicines were stopped during these two months to avoid interaction with the results of ^{14}C -UBT.

Assessment of ADRs and patient compliance

All patients were informed about potential ADRs, including pyrosis, anorexia, nausea, vomiting, bitter taste, abdominal colic, epigastric pain, headache, and back pain. The ADRs were evaluated during the intervention, using a 0–10 scoring system (mild: 0–3, the ADRs exist but insufferable; moderate: 4–6, ADRs sometimes interfere daily life activity; severe: 7–10, ADRs interfere continuously with daily life activities). Acceptable patient compliance was defined as consumption of $> 80\%$ of the prescribed medicines [30].

Statistical analyses

The eradication rate of two regimens was determined using Intention-to-treat (ITT) and per-protocol (PP) analysis. Patients declined to proceed with the treatment, or those with poor compliance were excluded from PP analysis; however, all patients, including patients who used the treatments out of the protocols or dropouts were included in ITT analysis. The eradication rate of *H. pylori*, odd ratios, and 95% confidence interval were evaluated for each regimen. Chi-square and *t* tests were employed to compare qualitative and quantitative variables between two treatment groups, respectively. All statistical analyses were performed using SPSS, version 18.0 software (SPSS Inc, Chicago, IL, United States). A $P < 0.05$ was considered statistically significant.

Results

Characteristics of the patients

A total of 220 patients with *H. pylori* infection were randomly assigned to either BPAL-7 ($n = 110$) or BPAL-10 ($n = 110$) groups. Three patients in the BPAL-7 group (one female with severe epigastric pain and diarrhea, and two males with severe anorexia and back pain) and one patient in the BPAL-10 group (one female with severe epigastric pain and nausea) were excluded from the trial because of drug intolerance and low compliance. A flow diagram describing patient selection and study outcomes is shown in Fig. 1.

No significant differences were observed between the two groups in terms of age, gender, cigarette smoking, alcohol drinking ($P > 0.05$). The Basic demographic characteristics of the patients are demonstrated in Table 1.

Table 1
Demographic characteristics of the study patients

Characteristics	BPAL-7 regimen (n = 107)	BPAL-10 regimen (n = 109)	P value
Gender, male	39 (36.5)	40 (36.7)	0.888
Age	41.46 ± 13.25	44.16 ± 12.70	0.649
Cigarette smoking			
Yes	4 (3.7)	7 (6.4)	0.353
No	103 (96.3)	102 (93.6)	
Alcohol drinking			0.313
Yes	1 (0.9)	3 (2.7)	
No	106 (99.1)	106 (97.3)	
Values were demonstrated as numbers (percentages) and Mean ± SD for categorical and continuous variables, respectively.			
Chi-square and <i>t</i> tests were performed to compare categorical and continuous variables between groups, respectively.			
BPAL-7 and BPAL-10; bismuth-based quadruple therapy containing pantoprazole, amoxicillin, and levofloxacin for seven and ten days, respectively.			

Eradication rates

The eradication rate of BPAL-7 regimen (49.1%, 95% CI: 39.3–57.8) was lower than that of BPAL-10 regimen (62.7%, 95% CI: 53.6–72.8) on ITT analysis (OR = 1.75, $P < 0.05$). Additionally, PP analysis also demonstrated a lower eradication rate in BPAL-7 regimen (47.6%, 95% CI: 39.7–58.4) compared to that of BPAL-10 regimen (62.4%, 95% CI: 55.1–72.8) (OR = 0.54, $P < 0.05$). The eradication rates of the two regimens are represented in Table 2. Univariate analyses were shown no association between age, gender, cigarette smoking, and alcohol drinking with an eradication rate of *H. pylori* in both groups ($P > 0.05$).

Table 2
The eradication rates of the BPAL-7 and BPAL-10 regimens.

Analyses	BPAL-7 regimen (n = 107)	BPAL-10 regimen (n = 109)	P value
Intention-to-treat	54 (49.1)	69 (62.7)	0.037
Per-protocol	51 (47.6)	68 (62.4)	0.024
Values were demonstrated as numbers (percentages).			
¹⁴ C-urea breath test was conducted to confirm the eradication of <i>H. pylori</i> two months after the end of treatment.			
Chi-square test was performed to compare variables between groups.			
BPAL-7 and BPAL-10; bismuth-based quadruple therapy containing pantoprazole, amoxicillin, and levofloxacin for seven and ten days, respectively.			

ADRs and patient compliances

Both BPAL-7 and BPAL-10 regimens were well-tolerated by a majority of patients. The number of patients with ADRs was not statistically significant between the BPAL-7 group (36 patients, 33.6%) and the BPAL-10 group (40 patients, 36.7%). ADRs were rated as mild (55 patients, 25%), moderate (17 patients, 7.7%), and severe (4 patients, 1.8%). The most-reported ADRs were epigastric pain, nausea, vomiting, and bitter taste in both regimens (Table 3).

Table 3
The adverse drug reactions associated with the BPAL-7 and BPAL-10 regimens.

ADRs	BPAL-7 (n = 107)			BPAL-10 (n = 109)		
	Mild	Moderate	Severe	Mild	Moderate	Severe
Pyrosis	31 (29.0)	4 (3.7)	1 (0.9)	23 (21.1)	10 (9.2)	1 (0.9)
Anorexia	25 (23.4)	4 (3.7)	2 (1.9)	21 (19.3)	4 (3.7)	1 (0.9)
Nausea	19 (17.8)	2 (1.8)	1 (0.9)	25 (22.9)	0 (0.0)	0 (0.0)
Vomiting	2 (1.9)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.9)
Bitter taste	19 (17.8)	0 (0.0)	1 (0.9)	10 (9.2)	2 (1.8)	1 (0.9)
Abdominal colic	12 (11.2)	0 (0.0)	0 (0.0)	9 (8.2)	3 (2.7)	0 (0.0)
Epigastric pain	17 (15.9)	7 (6.5)	1 (0.9)	22 (20.2)	3 (2.7)	1 (0.9)
Headache	15 (14.0)	2 (1.9)	1 (0.9)	16 (14.7)	7 (6.4)	1 (0.9)
Back pain	6 (5.6)	1 (0.9)	2 (1.9)	9 (8.3)	6 (5.5)	1 (0.9)
Values were demonstrated as numbers (percentages).						
Adverse drug reactions were evaluated during the study.						
Chi-square test was performed to compare variables between groups. None of variables were shown statistically significant differences between two regimens in each category.						
ADRs; adverse drug reactions, BPAL-7 and BPAL-10; bismuth-based quadruple therapy containing pantoprazole, amoxicillin, and levofloxacin for seven and ten days, respectively.						

The compliance rates were 97.3 % and 99.1 % for the BPAL-7 and PBAL-10 regimens, respectively. Three patients in the BPAL-7 regimen and one patient in the PBAL-10 regimen excluded from the PP analysis because of failure to ingest > 80 % of the medications.

Discussion

The finding of the present study showed a lower rate of *H. pylori* eradication in the BPAL-7 regimen compared to the BPAL-10 regimen among patients with dyspepsia and *H. pylori* infection. Both BPAL-7 and PBAL-10 regimens were well-tolerated and had acceptable patient compliance.

Recent guidelines suggest the eradication rate of triple therapy with a PPI, amoxicillin or metronidazole, and clarithromycin as first-line regimens have decreased, particularly due to an increase in microbial resistance to clarithromycin [1]. Moreover, some recommended bismuth-based quadruple therapy regimens also have an eradication rate of less than 80% [31]. Therefore, more effective regimens are needed to eradicate the *H. pylori* infection.

A body of evidence suggested to using levofloxacin, a new generation fluoroquinolone with in vitro anti-*H. pylori* activity, as an alternative agent in clarithromycin-resistant cases. Levofloxacin containing triple, quadruple, and sequential regimens have demonstrated a various range of eradication rates [32–34].

A study compared a triple therapy consisting of esomeprazole, levofloxacin (500 mg daily), and amoxicillin with a standard regimen consist of esomeprazole, metronidazole, bismuth, and tetracycline for a period of 14 days. The eradication rate of levofloxacin containing regimen (96.3%) was higher than the standard regimen (86.0%) in ITT analysis [24].

Gisbert *et al.* from Spain demonstrated the eradication rate of ranitidine bismuth citrate, levofloxacin, and amoxicillin as first-line triple therapy for *H. pylori* was 84.4 and ADRs, mainly including diarrhea, were reported in 9.5% of the patients [35]. This group carried out a trial with 1000 patients on the efficacy of omeprazole, levofloxacin, and amoxicillin for ten days. They reported an eradication rate of 73.8% and ADRs of 20%, which most commonly included nausea, metallic taste, and abdominal pain [25]. The dosage of levofloxacin was higher in these studies (500 mg twice a day). In a recent multicenter study conducted by Gisbert *et al.*, 14 days treatment by esomeprazole, amoxicillin, levofloxacin (500 mg daily), and bismuth as a rescue therapy achieved more than 90% of eradication rate [26]. In another Spanish study, the eradication rate of omeprazole, levofloxacin (500 mg twice a day), and amoxicillin combination for a ten-day period also had about 20% failure rate [36].

A study from Kosovo randomized 105 patients to either seven or ten days levofloxacin-based regimens, including omeprazole, levofloxacin (500 mg daily), and amoxicillin. The eradication rates were 86.2% and 93.6%, respectively. About 5% of patients experienced ADRs, mostly nausea and diarrhea [27].

Several Taiwanese studies evaluated the efficacy of levofloxacin-containing regimens as rescue therapy for the eradication of *H. pylori*. Kuo *et al.* reported the eradication rate of esomeprazole, amoxicillin, and levofloxacin (500 mg daily) regimen for seven days is similar to a second line quadruple standard regimens (about 60–70%) [37]. Four years later, the same group published a study comparing a levofloxacin-containing quadruple therapy (esomeprazole, bismuth, tetracycline, and 500 mg of levofloxacin once daily) for ten days with high-dose metronidazole- containing standard quadruple regimen. Based on their findings, eradication rates of about 80% was reached for both regimens [38]. On the other hand, Hsu *et al.* showed a ten-day quadruple therapy consist of esomeprazole, bismuth, tetracycline, and levofloxacin (500 mg daily) achieved a very high eradication rate (95.8%) at this geographical area. ADRs were detected in 25.0% of patients [39]. In another study, the efficacy of adding bismuth to a levofloxacin-based triple regimen (rabeprazole, bismuth, amoxicillin, and 500 mg of levofloxacin daily) assessed. The results revealed no further significant eradication rate (67.6%), but no more ADRs were noted [40].

According to the results of the present study, the BPAL-7 and the PBAL-10 regimens were not clinically successful in the treatment of *H. pylori* with an eradication rate of 62.7 % and 49.1 % by ITT analyses, respectively. Both regimens achieved neither cut point of an ideal regimen (eradication rate of > 90 %), nor acceptable eradication rate of Maastricht and other guidelines (> 80 %) [41]. The low efficacy of these

regimens is likely related to the regional pattern of bacterial resistance. The results of these regimens are consistent with a previous Iranian study evaluating the efficacy of a 14-day triple therapy, comprised of omeprazole, levofloxacin (500 mg daily), amoxicillin with success rate of 75 % [42]. However, studies conducted in other parts of Iran revealed fluoroquinolone-containing regimens including a 14-day of omeprazole, levofloxacin (250 mg twice a day) and amoxicillin as well as a 14-day of omeprazole, levofloxacin (500 mg twice a day), and amoxicillin as rescue therapies of *H. pylori* had eradication rate of 90 % and 86.7 %, respectively [43, 44]. Moreover, there are some other Iranian investigations that evaluated the efficacy of levofloxacin-based, sequential therapy in the treatment of *H. pylori*, and the eradication rate ranged from 70.8% to 85.1 % [45–47].

No relationship was observed between patient demographic characteristics including age, gender, cigarette smoking, and alcohol drinking and the success rate of both BPAL-7 and PBAL-10 regimens. Previous studies have also demonstrated the eradication rate of levofloxacin-containing regimens was not associated with age [45, 47, 44], gender [46, 45, 44], smoking status [48, 45], and education level [45].

Although high efficacy along with compatibility with the pattern of regional bacterial resistance are the main properties of an ideal pharmacological regimen for eradication of *H. pylori*, tolerability, patient compliance, simplicity, and cost-efficacy should not be neglected [30]. The compliance rates for the BPAL-7 and PBAL-10 regimens were 97.3 % and 99.1 %, respectively. In spite of high compliance rates, ADRs were reported in one-third of patients. The most-reported ADRs were epigastric pain, nausea, vomiting, and bitter taste. Generally, BPAL-7 and PBAL-10 regimens were patient compatible and well-tolerated.

Limitations

The main limitations of the present study are the lack of regional pattern of antibiotic resistance and a local estimate of *H. pylori* eradication rate as well as the small number of patients in the groups. The absence of pretreatment susceptibility assessment to levofloxacin is another drawback. Moreover, the finding may not be applicable to patients with previous treatment failure and recurrence disease.

Conclusion

The BPAL-7 and PBAL-10 regimens were patient compatible and well-tolerated. However, both regimens showed no satisfied eradication rate. Therefore, these regimens could not be ideal alternative therapies for *H. pylori* eradication in this region. It is better to evaluate the efficacy and tolerability of this regimen in other geographical regions, longer studies with more sample size.

Abbreviations

H. pylori: *Helicobacter pylori*; **ADRs**: adverse drug reactions; **PPI**: proton-pump inhibitor; **ITT**: intention-to-treat, **PP**: per-protocol, **BPAL-7**: bismuth-based quadruple therapy containing pantoprazole, amoxicillin, and levofloxacin for seven days; **BPAL-10**: bismuth-based quadruple therapy containing pantoprazole, amoxicillin, and levofloxacin for ten days

Declarations

Acknowledgments

The authors would especially like to thank the assistance and cooperation of the Health Deputy of Gastrointestinal and Liver Diseases Research Center (GLDRC) of Guilan University of Medical Sciences, Rasht, Iran. This study supported by Guilan University of Medical Sciences, Rasht, Iran.

Authors' contribution

FJ and FMG designed and supervised the procedure of the research. **FMG, HS**, and **BM** enrolled participants, collected data. **FJ, SH**, and **MS** analyzed data, and **MF, FJ, MA, AMG** and **MS** drafted the manuscript. **MF, SH** and **AMG** edited and revised the manuscript. **All authors** have read and approved the final draft of the paper.

Funding

The study was financially supported by a grant from Guilan University of Medical Sciences, Rasht, Iran (grant number: 1930175713). Our organization has helped us to provide principal materials and drugs.

Compliance with Ethical Standards

Conflicts of interest

The authors report no conflicts of interest in this work.

Role of Funding Source

Guilan University of Medical Sciences funded the study, but had no role in the execution of the study, patient recruitment or data collection.

References

1. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of *Helicobacter pylori* infection. Am J Gastroenterol. 2007;102(8):1808–25. doi:10.1111/j.1572-0241.2007.01393.x.
2. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao S, Tan HJ, Wu CY. Second Asia–Pacific consensus guidelines for *Helicobacter pylori* infection. J Gastroenterol Hepato. 2009;24(10):1587–600.
3. Shafaie S, Kaboosi H, Peyravii Ghadikolaii F. Prevalence of non *Helicobacter pylori* gastric *Helicobacters* in Iranian dyspeptic patients. BMC Gastroenterol. 2020;20(1):190–0. doi:10.1186/s12876-020-01331-x.

4. Khatibian M, Ajvadi Y, Nasser-Moghaddam S, Ebrahimi-Darjani N, Vahedi H, Zendehdel N, Sotoudehmanesh R, Agah S, Mikaeli J, Pourshams A, Ali-Asgari A, Malekzadeh R, Massarrat S. (2007) Furazolidone-based, metronidazole-based, or a combination regimen for eradication of *Helicobacter pylori* in peptic ulcer disease. Arch Iran Med 10 (2):161–167. doi:07102/AIM.007.
5. Malfertheiner P, Megraud F, O'morain CA, Atherton J, Axon A, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T. Management of *Helicobacter pylori* infection—the Maastricht IV/Florence consensus report. Gut. 2012;61(5):646–64.
6. Karatapanis S, Skorda L, Georgopoulos S, Papantoniou N, Papastergiou V, Ntoutsikos K, Komnianides K, Lisgos PH. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy as a second line treatment for the eradication of *H. pylori* infection. Ann Gastroenterol. 2009;22(4):263–7.
7. Wu W, Yang Y, Sun G. (2012) Recent insights into antibiotic resistance in *Helicobacter pylori* eradication. Gastroent Res and Pract 2012 (1):723183.
8. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-*Helicobacter pylori* quadruple therapies. Aliment Pharmacol Ther. 2004;20(10):1071–82. doi:10.1111/j.1365-2036.2004.02248.x.
9. Gisbert JP, Gonzalez L, Calvet X, Garcia N, Lopez T, Roque M, Gabriel R, Pajares JM. Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: a meta-analysis of eradication of *Helicobacter pylori*. Aliment Pharmacol Ther. 2000;14(10):1319–28. doi:10.1046/j.1365-2036.2000.00844.x.
10. Ahn HJ, Kim DP, Chu MS, Yun HJ, Kim SH, Lee SW, Lee DS. (2017) Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in *Helicobacter pylori* Infections. Gastroenterol Res Pract:6. doi:10.1155/2017/1654907.
11. Tai WC, Chiu CH, Liang CM, Chang KC, Kuo CM, Chiu YC, Wu KL, Hu ML, Chou YP, Chiou SS, Chiu KW, Kuo CH, Hu TH, Lin MT, Chuah SK. (2013) Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-*Helicobacter pylori* Eradication in Taiwan. Gastroenterol Res Pract:6. doi:10.1155/2013/932478.
12. Ohno A, Miyoshi J, Kato A, Miyamoto N, Yatagai T, Hada Y, Kusuha M, Jimbo Y, Ida Y, Tokunaga K, Okamoto S, Hisamatsu T. Endoscopic severe mucosal atrophy indicates the presence of gastric cancer after *Helicobacter pylori* eradication -analysis based on the Kyoto classification. BMC Gastroenterol. 2020;20(1):232. doi:10.1186/s12876-020-01375-z.
13. Song Z, Fu W, Zhou L. Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating *Helicobacter pylori* in patients allergic to penicillin. BMC Gastroenterol. 2019;19(1):132. doi:10.1186/s12876-019-1056-3.
14. Kabakambira JD, Hategeka C, Page C, Ntirenganya C, Dusabejambo V, Ndoli J, Ngabonziza F, Hale D, Bayingana C, Walker T. Efficacy of *Helicobacter pylori* eradication regimens in Rwanda: a randomized controlled trial. BMC Gastroenterol. 2018;18(1):134. doi:10.1186/s12876-018-0863-2.

15. Graham DY, Lee S-Y. How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. *Gastroenterol Clin North Am*. 2015;44(3):537–63. doi:10.1016/j.gtc.2015.05.003.
16. Mansour-Ghanaei F, Samadi A, Joukar F, Tirgar Fakheri H, Hassanipour S, Ashoobi MT, Soltanipour S, Alizadeh A, Rezamand G, Fathalipour M. Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of *Helicobacter pylori*: a randomized, double-blind clinical trial. *EXCLI J*. 2019;18(1):644–52. doi:10.17179/excli2019-1613.
17. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. *Gut*. 2004;53(9):1374–84. doi:10.1136/gut.2003.022111.
18. Graham DY, Qureshi WA. Antibiotic-resistant H. pylori infection and its treatment. *Curr Pharm Design*. 2000;6(15):1537–44. doi:10.2174/1381612003399077.
19. Jafar S, Jalil A, Soheila N, Sirous S. Prevalence of helicobacter pylori infection in children, a population-based cross-sectional study in west iran. *Iran J Pediatr*. 2013;23(1):13–8.
20. Nouraie M, Latifi-Navid S, Rezvan H, Radmard AR, Maghsudlu M, Zaer-Rezaei H, Amini S, Siavoshi F, Malekzadeh R. Childhood hygienic practice and family education status determine the prevalence of *Helicobacter pylori* infection in Iran. *Helicobacter*. 2009;14(1):40–6. doi:10.1111/j.1523-5378.2009.00657.x.
21. Salmanroghani H, Mirvakili M, Baghbanian M, Salmanroghani R, Sanati G, Yazdian P. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of *Helicobacter Pylori* in Patients with Duodenal Ulcer: A Randomized Clinical Trial. *PloS one*. 2018;13(6):e0197096. doi:10.1371/journal.pone.0197096.
22. Ebrahimi-Dariani N, Mirmomen S, Mansour-Ghanaei F, Noormohammadpoor P, Sotodehmanesh R, Haghpanah B, Bahrami H. The efficacy of furazolidone-based quadruple therapy for eradication of *Helicobacter pylori* infection in Iranian patients resistant to metronidazole-based quadruple therapy. *Medical science monitor: international medical journal of experimental clinical research*. 2003;9(8):PI105–108.
23. An B, Moon BS, Kim H, Lim HC, Lee YC, Lee G, Kim SH, Park M, Kim JB. Antibiotic resistance in *Helicobacter pylori* strains and its effect on H. pylori eradication rates in a single center in Korea. *Ann Lab Med*. 2013;33(6):415–9. doi:10.3343/alm.2013.33.6.415.
24. Chuah S, Tai W, Hsu P, Wu D, Wu K, Kuo C, Chiu Y, Hu M, Chou Y, Kuo Y. The efficacy of second-line anti-*Helicobacter pylori* therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment—a pilot study. *Helicobacter*. 2012;17(5):374–81.
25. Gisbert JP, Perez-Aisa A, Bermejo F, Castro-Fernandez M, Almela P, Barrio J, Cosme A, Modolell I, Bory F, Fernandez-Bermejo M, Rodrigo L, Ortuno J, Sanchez-Pobre P, Khorrami S, Franco A, Tomas A, Guerra I, Lamas E, Ponce J, Calvet X. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. *J Clin Gastroenterol*. 2013;47(2):130–5. doi:10.1097/MCG.0b013e318254ebdd.

26. Gisbert JP, Romano M, Gravina AG, Solís-Muñoz P, Bermejo F, Molina-Infante J, Castro-Fernández M, Ortuño J, Lucendo AJ, Herranz M. *Helicobacter pylori* second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. *Aliment Pharmacol Ther.* 2015;41(8):768–75.
27. Telaku S, Manxhuka-Kerliu S, Kraja B, Qirjako G, Prifti S, Ejza H. The efficacy of levofloxacin –based triple therapy for first –line *Helicobacter pylori* eradication. *Medical Archives.* 2013;67(1):348–50.
28. Chang S-P, Lee H-Z, Lai C-C, Tang H-J. The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials. *Infect Drug Resist.* 2019;12:433–8. doi:10.2147/IDR.S193233.
29. Chen C-W, Chen Y-H, Cheng I-L, Lai C-C. Comparison of high-dose, short-course levofloxacin treatment vs conventional regimen against acute bacterial infection: meta-analysis of randomized controlled trials. *Infect Drug Resist.* 2019;12:1353.
30. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. *Gut.* 2007;56(6):772–81. doi:10.1136/gut.2006.101634.
31. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of *Helicobacter pylori* infection. *Digestion.* 2013;88(1):33–45. doi:10.1159/000350719.
32. Chen PY, Wu MS, Chen CY, Bair MJ, Chou CK, Lin JT, Liou JM. Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of *Helicobacter pylori* infection. *Aliment Pharmacol Ther.* 2016;44(5):427–37. doi:10.1111/apt.13712.
33. Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of *Helicobacter pylori*? A systematic review and meta-analysis. *Scand J Gastroenterol.* 2014;49(5):528–38. doi:10.3109/00365521.2014.887765.
34. Ye CL, Liao GP, He S, Pan YN, Kang YB, Zhang ZY. Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for *Helicobacter pylori* eradication. *Pharmacoepidemiol Drug Saf.* 2014;23(5):443–55. doi:10.1002/pds.3581.
35. Gisbert JP, Fernandez-Bermejo M, Molina-Infante J, Perez-Gallardo B, Prieto-Bermejo AB, Mateos-Rodriguez JM, Robledo-Andres P, Gonzalez-Garcia G. First-line triple therapy with levofloxacin for *Helicobacter pylori* eradication. *Aliment Pharmacol Ther.* 2007;26(3):495–500. doi:10.1111/j.1365-2036.2007.03384.x.
36. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, Hernandez-Alonso M, Vinagre G, Duenas C, Mateos-Rodriguez JM, Gonzalez-Garcia G, Abadia EG, Gisbert JP. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for *Helicobacter pylori* eradication. *Aliment Pharmacol Ther.* 2010;31(10):1077–84. doi:10.1111/j.1365-2036.2010.04274.x.
37. Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ, Tsai PY, Wu IC, Wang SW, Li CJ, Weng BC, Chang LL, Jan CM, Wang WM, Wu DC. Efficacy of levofloxacin-based rescue therapy for *Helicobacter pylori*

- infection after standard triple therapy: a randomized controlled trial. *J Antimicrob Chemother.* 2009;63(5):1017–24. doi:10.1093/jac/dkp034.
38. Kuo CH, Hsu PI, Kuo FC, Wang SS, Hu HM, Liu CJ, Chuah SK, Chen YH, Hsieh MC, Wu DC, Tseng HH. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line *Helicobacter pylori* therapy: a randomized controlled trial. *J Antimicrob Chemother.* 2013;68(1):222–8. doi:10.1093/jac/dks361.
 39. Hsu PI, Chen WC, Tsay FW, Shih CA, Kao SS, Wang HM, Yu HC, Lai KH, Tseng HH, Peng NJ, Chen A, Kuo CH, Wu DC. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for *Helicobacter pylori* infection after failure of sequential therapy. *Helicobacter.* 2014;19(1):74–9. doi:10.1111/hel.12085.
 40. Wu TS, Hsu PI, Kuo CH, Hu HM, Wu IC, Wang SSW, Chen YH, Wu DC, Su WW, Kuo FC. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for *Helicobacter pylori*. *Journal of digestive diseases.* 2017;18(9):537–42. doi:10.1111/1751-2980.12498.
 41. Gao XZ, Qiao XL, Song WC, Wang XF, Liu F. Standard triple, bismuth pectin quadruple and sequential therapies for *Helicobacter pylori* eradication. *World journal of gastroenterology.* 2010;16(34):4357–62. doi:10.3748/wjg.v16.i34.4357.
 42. Haji-Aghamohammadi AA, Bastani A, Miroliaee A, Oveisi S, Safarnezhad S. Comparison of levofloxacin versus clarithromycin efficacy in the eradication of *Helicobacter pylori* infection. *Caspian J Intern Med.* 2016;7(4):267–71.
 43. Abangah G, Raughani A, Asadollahi P, Asadollahi K. (2019) Comparison between the two drug regimens of PPI + Amoxicillin + Rifampicin and PPI + Amoxicillin + Levofloxacin for the treatment of *H. pylori* infections resistant to the first line drug regimen among patients referred to Ilam clinics. *Gastroenterology and hepatology from bed to bench* 12 (3):209–216.
 44. Seyyedmajidi M, Abbasi L, Seyedmajidi S, Hosseini SA, Ahmadi A, Hajiebrahimi S, Vafaeimanesh J. Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti- *Helicobacter pylori*. *Caspian J Intern Med.* 2019;10(2):211–6. doi:10.22088/cjim.10.2.211.
 45. Moradniani M, Mirbeik-Sabzevari Z, Jaferian S, Shafieezadeh S, Ehsani Ardakani MJ, Mirzaee Roozbahany M, Azadbakht S, Sherkatolabbasieh H. (2018) Levofloxacin based vs clarithromycin based sequential therapy in *helicobacter pylori* eradication; a randomized clinical trial. *Gastroenterology and hepatology from bed to bench* 11 (1):19–26.
 46. Hajiani E, Alavinejad P, Avandi N, Masjedizadeh AR, Shayesteh AA. Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for *Helicobacter Pylori* Eradication: A Randomized Clinical Trial. *Middle East J Dig Dis.* 2018;10(4):242–8. doi:10.15171/mejdd.2018.117.
 47. Sebghatollahi V, Soheilipour M, Khodadoostan M, Shavakhi A, Shavakhi A. Levofloxacin-containing versus Clarithromycin-containing Therapy for *Helicobacter pylori* Eradication: A Prospective

Randomized Controlled Clinical Trial. Advanced biomedical research. 2018;7(1):55–67.
doi:10.4103/abr.abr_133_17.

48. Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, Chiu YC, Hu ML, Chou YP, Kuo YH, Liang CM, Chiu KW, Hu TH. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment–a pilot study. Helicobacter. 2012;17(5):374–81. doi:10.1111/j.1523-5378.2012.00960.x.

Figures

Figure 1

Flow chart for process of patient randomization. ITT; intention-to-treat, PP; per-protocol, ADRs; adverse drug reactions, BPAL-7 and BPAL-10; bismuth-based quadruple therapy containing pantoprazole, amoxicillin, and levofloxacin for seven and ten days, respectively.